AR017266A1 - Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm - Google Patents
Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farmInfo
- Publication number
- AR017266A1 AR017266A1 ARP980104793A ARP980104793A AR017266A1 AR 017266 A1 AR017266 A1 AR 017266A1 AR P980104793 A ARP980104793 A AR P980104793A AR P980104793 A ARP980104793 A AR P980104793A AR 017266 A1 AR017266 A1 AR 017266A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- homocyclic
- independently selected
- modulate
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title 1
- 239000002131 composite material Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 150000002148 esters Chemical class 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 229920006395 saturated elastomer Polymers 0.000 abstract 4
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 4
- 125000004417 unsaturated alkyl group Chemical group 0.000 abstract 4
- 150000007942 carboxylates Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto de azabenzoimidazolico que posee una estructura descripta por las formulas I, II o III, en donde (a) R1, R2, R3, y R4 se seleccionanindependientemente del grupo que integran: (i) hidrogeno; (ii) alquilo saturado o no saturado; (iii) NX2X3, donde X2 y X3 se seleccionan independientemente delgrupo que integran: hidrogeno, alquilo saturado o no saturado, y anillos homocíclicos o heterocíclicos; (iv) halogeno o trihalometilo; (v) una cetona deformula -CO-X4, donde X4 se selecciona del grupo que conforman hidrogeno, alquilo,y anillos homocíclicos o heterocíclicos; (vi) un ácido carboxílico de formula-(X5)n-COOH o éster de formula -(Xb)n-COO-X7 donde X5, X6 y X7 se seleccionan independientemente del grupo que integran alquilo o anillos homocíclicos oheterocíclicos, y donde n vale 0 o 1; (vii) un alcohol de formula (X8)n-OH o un grupo alcoxi de formula -(X8)n-O-X9, donde X8 y X9 se eligenindependientemente del grupo que conforman hidrogeno, alquilo saturado o no saturado, y anillos homocíclicos o heterocíclicos, donde el anillo se sustituyeopcionalmente con uno o varios sustituyentes elegidos del grupo que integran alquilo, alcoxi, halogeno, trihalometilo, carboxilato, nitro y éster, y donde nvale 0 o 1; (viii) una amida deformula -NHCOX10, donde X10 se selecciona del grupo que integran alquilo, hidroxilo, y anillos homocíclicos o heterocíclicos, ydonde el anillo se sustituye opcionalmente con uno o varios sustituyentes independientemente seleccionados del grupo que conforman alquilo, alcoxi, halogeno,trihalometilo, carboxilato, nitro y éster; (ix) -SO2NX33X12, donde X33 y X32 se seleccionan del grupo que integran hidrogeno, alquilo y anillos homocíclicos oheterocíclicos; (x) un anillo homocíclico o heterocíclicosustituido con uno, dos o tres sustituyentes seleccionados independientemente del grupo que conformanalquilo, alcoxi, halogeno, trihalometilo, caboxilato, nitro y éster; (xi) un aldehído de formula -CO-H; y (xii) una sulfona de formula -SO2-X13, donde X13 seelige del grupo que conforman alquilo saturado o no saturado y anillos homocíclicos o heterocíclicos; (b) Z1 y Z2 se seleccionan independientemente del grupo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6014597P | 1997-09-26 | 1997-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017266A1 true AR017266A1 (es) | 2001-09-05 |
Family
ID=22027657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980104793A AR017266A1 (es) | 1997-09-26 | 1998-09-25 | Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6093728A (es) |
| EP (1) | EP1017384B1 (es) |
| JP (1) | JP2001517699A (es) |
| KR (1) | KR100547929B1 (es) |
| CN (1) | CN1167420C (es) |
| AR (1) | AR017266A1 (es) |
| AT (1) | ATE281834T1 (es) |
| AU (1) | AU748849B2 (es) |
| BG (1) | BG64784B1 (es) |
| BR (1) | BR9812682A (es) |
| CA (1) | CA2305370C (es) |
| DE (1) | DE69827516T2 (es) |
| DK (1) | DK1017384T3 (es) |
| ES (1) | ES2230719T3 (es) |
| HU (1) | HUP0004024A3 (es) |
| IL (4) | IL158649A0 (es) |
| NO (1) | NO325663B1 (es) |
| NZ (2) | NZ503432A (es) |
| PL (1) | PL191618B1 (es) |
| PT (1) | PT1017384E (es) |
| RU (1) | RU2230553C2 (es) |
| SK (1) | SK285357B6 (es) |
| TR (1) | TR200001546T2 (es) |
| TW (1) | TW581815B (es) |
| UA (1) | UA72448C2 (es) |
| WO (1) | WO1999016438A1 (es) |
| ZA (1) | ZA988797B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142236A1 (en) * | 1994-05-31 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6384049B1 (en) * | 2000-05-25 | 2002-05-07 | The Procter & Gamble Company | Cancer treatment |
| JP2004528304A (ja) * | 2001-03-12 | 2004-09-16 | アバニール・ファーマシューティカルズ | ＩｇＥを調節し、細胞増殖を阻害するためのベンゾイミダゾール化合物 |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| TWI276631B (en) * | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| US20050256179A1 (en) * | 2003-08-08 | 2005-11-17 | Sircar Jagadish C | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| WO2007062222A2 (en) * | 2005-11-22 | 2007-05-31 | University Of South Florida | Inhibition of cell proliferation |
| WO2007125330A1 (en) | 2006-04-26 | 2007-11-08 | Cancer Research Technology Limited | Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds |
| ES2631003T3 (es) | 2006-10-19 | 2017-08-25 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y métodos de tratamiento con ellos |
| US8748371B2 (en) * | 2007-02-28 | 2014-06-10 | Yeda Research And Development Co. Ltd. | Nuclear targeting sequences |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| EP2181987B9 (en) | 2007-08-23 | 2014-09-03 | Takeda Pharmaceutical Company Limited | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer |
| EP2184285B1 (en) * | 2007-08-29 | 2015-11-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2010025448A2 (en) * | 2008-08-29 | 2010-03-04 | University Of South Florida | Inhibition of cell proliferation |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US8697874B2 (en) | 2008-12-01 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
| JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体 |
| KR20120091240A (ko) | 2009-10-26 | 2012-08-17 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| EP2531502B1 (en) | 2010-02-01 | 2014-04-02 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
| SG10201604558SA (en) | 2011-12-02 | 2016-07-28 | Signal Pharm Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4 methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| JP6114317B2 (ja) | 2012-02-24 | 2017-04-12 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EA201591327A1 (ru) | 2013-01-16 | 2015-12-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений |
| EP2970277B1 (en) * | 2013-03-15 | 2021-07-28 | Knopp Biosciences LLC | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| TWI631949B (zh) | 2013-04-17 | 2018-08-11 | 標誌製藥公司 | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| SG10201708111YA (en) | 2013-04-17 | 2017-11-29 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| CA2909629C (en) | 2013-04-17 | 2022-12-13 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| MX377267B (es) | 2013-04-17 | 2025-03-07 | Signal Pharm Llc | Tratamiento de cáncer con dihidropirazino-pirazinas. |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| TW201521725A (zh) | 2013-04-17 | 2015-06-16 | Signal Pharm Llc | 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法 |
| CA3143529A1 (en) | 2013-05-29 | 2014-12-04 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions 0f 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| ES2717446T3 (es) | 2013-09-17 | 2019-06-21 | Yeda Res & Dev | Péptidos derivados de ERK y usos de los mismos |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| SI3572405T1 (sl) | 2014-09-12 | 2023-12-29 | Biohaven Therapeutics Ltd. | Amidi benzoimidazol-1,2-il kot aktivatorji kanalov kv 7 |
| BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590045A (en) * | 1969-09-25 | 1971-06-29 | Smith Kline French Lab | Certain substituted imidazo (4,5-b)pyridines |
| BE788065A (fr) | 1971-08-26 | 1973-02-26 | Degussa | Nouvelles aza-benzimidazoles et procede pour leur preparation |
| SE422799B (sv) | 1975-05-28 | 1982-03-29 | Merck & Co Inc | Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner |
| ES473201A1 (es) * | 1977-09-26 | 1979-03-16 | Degussa | Procedimiento para la preparacion de 7-azabencimidazoles |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| EP0526488B1 (en) * | 1990-04-02 | 1994-11-30 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| EP0584222B1 (en) * | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| CA2108889A1 (en) * | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| GB9300059D0 (en) * | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| WO1994003427A1 (en) * | 1992-08-06 | 1994-02-17 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US5582995A (en) | 1993-06-11 | 1996-12-10 | The General Hospital Corporation | Methods of screening for compounds which inhibit the direct binding of Ras to Raf |
| EP0707585A1 (en) * | 1993-07-06 | 1996-04-24 | Pfizer Inc. | Bicyclic tetrahydro pyrazolopyridines |
| US5645982A (en) * | 1993-08-19 | 1997-07-08 | Systemix, Inc. | Method for screening potential therapeutically effective antiviral agents |
| GB9501567D0 (en) * | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
-
1998
- 1998-09-23 PL PL339744A patent/PL191618B1/pl not_active IP Right Cessation
- 1998-09-23 DE DE69827516T patent/DE69827516T2/de not_active Expired - Fee Related
- 1998-09-23 UA UA2000042349A patent/UA72448C2/uk unknown
- 1998-09-23 EP EP98949464A patent/EP1017384B1/en not_active Expired - Lifetime
- 1998-09-23 AU AU95781/98A patent/AU748849B2/en not_active Ceased
- 1998-09-23 ES ES98949464T patent/ES2230719T3/es not_active Expired - Lifetime
- 1998-09-23 WO PCT/US1998/019973 patent/WO1999016438A1/en not_active Ceased
- 1998-09-23 HU HU0004024A patent/HUP0004024A3/hu unknown
- 1998-09-23 RU RU2000110736/15A patent/RU2230553C2/ru not_active IP Right Cessation
- 1998-09-23 US US09/160,212 patent/US6093728A/en not_active Expired - Fee Related
- 1998-09-23 CA CA002305370A patent/CA2305370C/en not_active Expired - Fee Related
- 1998-09-23 TR TR2000/01546T patent/TR200001546T2/xx unknown
- 1998-09-23 NZ NZ503432A patent/NZ503432A/xx unknown
- 1998-09-23 KR KR1020007003192A patent/KR100547929B1/ko not_active Expired - Fee Related
- 1998-09-23 SK SK415-2000A patent/SK285357B6/sk unknown
- 1998-09-23 BR BR9812682-2A patent/BR9812682A/pt not_active Application Discontinuation
- 1998-09-23 PT PT98949464T patent/PT1017384E/pt unknown
- 1998-09-23 IL IL15864998A patent/IL158649A0/xx not_active IP Right Cessation
- 1998-09-23 CN CNB988107538A patent/CN1167420C/zh not_active Expired - Fee Related
- 1998-09-23 DK DK98949464T patent/DK1017384T3/da active
- 1998-09-23 IL IL13510998A patent/IL135109A0/xx not_active IP Right Cessation
- 1998-09-23 AT AT98949464T patent/ATE281834T1/de not_active IP Right Cessation
- 1998-09-23 JP JP2000513574A patent/JP2001517699A/ja not_active Withdrawn
- 1998-09-25 AR ARP980104793A patent/AR017266A1/es unknown
- 1998-09-25 TW TW087115979A patent/TW581815B/zh not_active IP Right Cessation
- 1998-09-25 ZA ZA9808797A patent/ZA988797B/xx unknown
-
2000
- 2000-03-15 IL IL135109A patent/IL135109A/en unknown
- 2000-03-24 NO NO20001555A patent/NO325663B1/no unknown
- 2000-04-19 BG BG104356A patent/BG64784B1/bg unknown
-
2002
- 2002-03-15 NZ NZ517808A patent/NZ517808A/en unknown
- 2002-11-15 US US10/294,802 patent/US6855723B2/en not_active Expired - Fee Related
-
2003
- 2003-10-29 IL IL158649A patent/IL158649A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017266A1 (es) | Compuesto azabenzoimidazolico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farm | |
| AR013542A1 (es) | Compuesto 5-azaquinoxalinico, composicion farmaceutica que lo comprende, metodo para sintetizarlo, metodo para modular la funcion de una serina/treoninaproteina-quinasa con dicho compuesto, metodo para identificar compuestos que modulan tal funcion y uso del mismo para preparar una composicion farma | |
| UA74391C2 (uk) | Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти | |
| AR005053A1 (es) | Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv | |
| BR9910971A (pt) | Composto, processos para a preparação de um composto e para produzir um efeito antibacteriano em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
| HUP9700358A2 (hu) | Új oxazolidinonszármazékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
| CO5601011A2 (es) | Derivados de 3-ciclil-5-(anillo de 5 miembros que contiene nitrogeno) metil-oxazolidinona y su uso como agentes antibacterianos | |
| EA200401613A1 (ru) | Лекарственное средство для лечения рака | |
| PE20011067A1 (es) | Glutarimidas sustituidas, su preparacion, medicamentos que las contienen, y uso de las mismas para la fabricacion de medicamentos, especialmente inmunomoduladores, como asi tambien inhibidores de angiopatias y/o enfermedades hematologicas/oncologicas | |
| MX9102209A (es) | Derivados de acido hidroxamico y n-hidroxiurea novedosos y su uso. | |
| ES2160747T3 (es) | 2-(indan-1-ona-2-il-alquil)-1-fenilalquil-piperidinas y procedimientos para su preparacion. | |
| SE9302080D0 (sv) | New compounds | |
| DE69914478D1 (de) | Oxazolidinon-derivate als antibiotika, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen | |
| ATE301460T1 (de) | Zubereitung zur prophylaxe oder behandlung der demenz-erkrankung enthaltend ein hydroxyzimtsäurederivat oder einen extrakt einer pflanze der gattung angelica, der diese säure enthält. | |
| EA200401615A1 (ru) | ИНГИБИТОРЫ АКТИВАЦИИ NF-kB | |
| AR016175A1 (es) | Compuestos derivados del acido dihidroxihexanoico, su uso para la preparacion de medicamentos y composiciones de los mismos. | |
| EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
| ATE253571T1 (de) | 2-heterozyklisch-5-hydroxy-1,3-pyrimidinen verwendbar als entzündungswidrigesmittel | |
| YU13299A (sh) | Postupak i intermedijari za dobijanje hromanolnih derivata | |
| DE60139409D1 (de) | Pharmazeutische zusammensetzungen die ein dibenzocyclooctanlignanderivat enthalten zur vorbeugung und behandlung neurodegenerativer erkrankungen | |
| FI953566A0 (fi) | Tahdospironia tai sen analogeja sisältäviä koostumuksia | |
| ATE18221T1 (de) | (1-arylcyclobutyl)(heterocyclyl)methylaminderivate, ihre herstellung und ihre verwendung als arzneimittel. | |
| AR036028A1 (es) | Compuesto de pirimidina, procedimiento para su preparacion, composiciones farmaceuticas formuladas con dichos compuestos y uso de los compuestos en la preparacion de las composiciones mencionadas | |
| DK0891346T3 (da) | Dihydrobenzofuranforbindelser, der er nyttige som antiinflammatoriske midler | |
| ATE127465T1 (de) | Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |